Event – Melbourne: What is the meaning of Myriad?
Prior to the High Court of Australia decision in D’Arcy v Myriad Genetics Inc., handed down on 7 October 2015, the law in Australia governing what types of technologies could be patent protected was relatively clear. In the wake of the Myriad decision all of this could change. Although the decision relates directly to human genes the impact of the decision could be far reaching, potentially affecting patent protection on gene technologies more generally, naturally occurring chemicals, ICT inventions and other new technologies.
DCC and BioMelbourne welcome you to learn about the background and impact of the decision and IP Australia’s interpretation of it. The practical effects of the decision will be discussed by our expert panel with delegate interaction.
The Sydney seminar, co-hosted with AusBiotech, is available here to view below, and includes quick link chapter markers allowing you to skip to each presentation.
|WHERE||Davies Collison Cave
Level 15, 1 Nicholson Street
East Melbourne VIC 3000
|WHEN||Thursday 19th November 2015
5.00pm refreshments on arrival 5.15pm event start
Networking drinks to follow
Friday 13th November by email to email@example.com
View full version on the invitation here